Drug Trial Radar · NCT01222247
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Last checked: Nov 19, 2026Latest source record: Mar 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,831
Actual
Start
Oct 2010
Primary completion
Mar 2015
Study completion Aug 31, 2022
Sponsor
- Lead sponsor
- The George Washington University Biostatistics CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- Oct 18, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized placebo controlled trial to evaluate whether antenatal corticosteroids can decrease the rate of neonatal respiratory support, thus decreasing the rate of NICU admissions and improving short-term outcomes in the late preterm infant. The use of antenatal corticosteroids has been shown to be beneficial in women at risk for preterm delivery prior to 34 weeks but has not been evaluated in those likely to deliver in the late preterm period
Conditions
- Pregnancy
- Respiratory Distress Syndrome
- Pregnancy Outcomes
- Preterm Birth
Interventions
BetamethasoneDrug
The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.
PlaceboDrug
Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Neonatal Composite OutcomeTime frame: 72 hours of life
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama - Birmingham
Birmingham, Alabama
Stanford University
Stanford, California
University of Colorado
Denver, Colorado
Northwestern University
Chicago, Illinois
Wayne State University
Detroit, Michigan
Columbia University
New York, New York
University of North Carolina - Chapel Hill
Chapel Hill, North Carolina
Duke University
Durham, North Carolina
Case Western Reserve University
Cleveland, Ohio
Ohio State University
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
University of Pittsburgh Magee Womens Hospital
Pittsburgh, Pennsylvania
Brown University
Providence, Rhode Island
University of Texas - Southwest
Dallas, Texas
University of Texas - Galveston
Galveston, Texas
University of Texas - Houston
Houston, Texas
University of Utah Medical Center
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.